[Articles] Efficacy and safety of cemdisiran siRNA in myasth

Cemdisiran shows effectiveness and safety for treating myasthenia gravis in phase 3 trial

A new drug called cemdisiran showed promise in treating generalised myasthenia gravis, a condition that causes muscle weakness and fatigue. Given as a shot every three months, the treatment was effective and well tolerated in clinical trials. This could offer patients a more convenient option than current therapies that require frequent dosing.